Table 3 Time-to-seizure occurrence by multivariable proportional hazard regression analysis in patients in the LUMINA cohort*

Variable	HR (95% CI)	p Value
Younger age, years	1.04 (1.00 to 1.08)	0.0304
SLAM-R†	1.10 (1.04 to 1.15)	0.0004
Mucocutaneous manifestations	0.34 (0.16 to 0.41)	0.0039
Hydroxychloroquine use	0.35 (0.15 to 0.80)	0.0131

LUMINA, LUpus in MInorities: NAture versus Nurture.
*Adjusted for gender, ethnicity, marital status, disease duration, damage accrual (seizures excluded), disease manifestations (musculoskeletal, psychosis and renal damage) and medications (cyclophosphamide, average dose of glucocorticoids).
†Systemic Lupus Activity Measure-Revised at baseline (seizures excluded).
For alternative analyses, please refer to text.